Human breast cancer cell lines MCF10A, MDA-MB-468 (MDA-468), BT20, and MDA-MB-231 (MDA-231) were purchased from ATCC (Manassas, VA, USA) and cultured as instructed. Bone-metastatic MDA-MB-231BoM (231-BoM), and brain-metastatic MDA-MB-231BrM (231-BrM) cell lines are from the Massagué laboratory and were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin [43 (link), 44 (link)]. Trastuzumab-resistant BT474 (BT474-TtzmR) were a kind gift from Dr. Dihua Yu [45 (link)]. All cell lines have been authenticated using the standard method, and tested for mycoplasma. If tested positive for mycoplasma contamination, cells were treated until free of contamination before use. Pacritinib, ruxolitinib, sonidegib, and vismodegib were obtained from AdooQ Bioscience (Irvine, CA, USA) and stock solutions were prepared using dimethyl sulfoxide (DMSO) for administration in cell culture.
Ruxolitinib
Manufactured by Adooq
Sourced in United States
Ruxolitinib is a small-molecule inhibitor. It functions by targeting and inhibiting the Janus kinase (JAK) family of enzymes, which are involved in cellular signaling pathways.
Automatically generated - may contain errors
Lab products found in correlation
Sonidegib, by Adooq (2 mentions)
Vismodegib, by Adooq (2 mentions)
Pacritinib, by Adooq (2 mentions)
Mda mb 468, by American Type Culture Collection (2 mentions)
Mcf 10a, by American Type Culture Collection (2 mentions)
Mda mb 231, by American Type Culture Collection (2 mentions)
Vincristine sulfate, by Merck Group (1 mentions)
Reparixin, by Merck Group (1 mentions)
Oxaliplatin, by Merck Group (1 mentions)
Peg300, by Merck Group (1 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (1 mentions)
Tween 80, by Daejung Chemicals (1 mentions)
Trametinib, by Adooq (1 mentions)
Afatinib, by Adooq (1 mentions)
Dasatinib, by Adooq (1 mentions)
Lenvatinib, by Adooq (1 mentions)
Regorafenib, by LGC (1 mentions)
Gefitinib, by Cayman Chemical (1 mentions)
Elacridar, by LGC (1 mentions)
Ponatinib, by Adooq (1 mentions)
4 protocols using ruxolitinib
1
Breast Cancer Cell Lines and Inhibitors
2
Breast Cancer Cell Lines and Inhibitors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Human breast cancer cell lines MCF10A, MDA-MB-468 (MDA-468), BT20, and MDA-MB-231 (MDA-231) were purchased from ATCC (Manassas, VA, USA) and cultured as instructed. Bone-metastatic MDA-MB-231BoM (231-BoM), and brain-metastatic MDA-MB-231BrM (231-BrM) cell lines are from the Massagué laboratory and were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin [43 (link), 44 (link)]. Trastuzumab-resistant BT474 (BT474-TtzmR) were a kind gift from Dr. Dihua Yu [45 (link)]. All cell lines have been authenticated using the standard method, and tested for mycoplasma. If tested positive for mycoplasma contamination, cells were treated until free of contamination before use. Pacritinib, ruxolitinib, sonidegib, and vismodegib were obtained from AdooQ Bioscience (Irvine, CA, USA) and stock solutions were prepared using dimethyl sulfoxide (DMSO) for administration in cell culture.
3
Preparation of Anticancer Drug Solutions
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Solutions of vincristine sulfate (Sigma Aldrich, St. Louis, MO, USA), oxaliplatin (Sigma Aldrich, St. Louis, MO, USA), reparixin (Sigma Aldrich, St. Louis, MO, USA), and ruxolitinib (Adooq Bioscience, Irvine, CA, USA) were prepared in 5% DMSO (Sigma Aldrich, St. Louis, MO, USA), 40% PEG300 (Sigma Aldrich, St. Louis, MO, USA), 5% tween 80 (Daejung Chemicals and Metals, Siheung-si, Republic of Korea), and 50% saline (Daihan Pharm, Seoul, Republic of Korea).
4
Cell-based Assay of Multi-Targeted Kinase Inhibitors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Regorafenib, M-2, M-5, and elacridar were purchased from Toronto Research Chemicals (North York, ON). Ko143 was from Sigma-Aldrich (St. Louis, MO). Imatinib mesylate was from Focus Biomolecules (Plymouth Meeting, PA). Afatinib, bortezomib, cabozantinib, carfilzomib, dabrafenib, dacomitinib, dasatinib, lapatinib, lenvatinib, pazopanib, ponatinib, ruxolitinib, tofacitinib, trametinib, vandetanib, and vemurafenib were from AdooQ Bioscience (Irvine, CA). Sorafenib was from LKT Laboratories Inc. (St. Paul, MN). Sunitinib was from Synkinase Pty Ltd. (San Diego, CA). Crizotinib was from LC Laboratories Inc. (Woburn, MA). Gefitinib and erlotinib were from Cayman Chemical Company (Ann Arbor, MI). Nilotinib was from ChemScene, LLC (Monmouth Junction, NJ). All other chemicals and reagents were of analytical grade and were obtained from commercial sources.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!